ArticleAnnals of medicine2025
Risk of serious bacterial infections in inflammatory rheumatic or bowel disease patients during biological therapies: nationwide Danish cohort study.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo estimate the incidence rate ratio (IRR) of serious bacterial infections (SI) in patients with inflammatory bowel disease (IBD) or inflammatory rheumatic disease (IRD) before and after initiating biological therapy, and to assess comorbidities, infection sites, and the type of biological therapy.
methodsThis nationwide retrospective registry-based study used a cohort-crossover design to assess the relative risk of SI one year before and after treatment. Data from the Danish National Patient Registry included 20,216 patients with IBD or IRD. Diagnosis codes for hospital contacts (inpatients, outpatients, day patients, and emergency department patients) and hospital-treated bacterial infections from 1994 to 2018 were linked using the Civil Registration System.
resultsThere were 1235 infections during 19,529 person-years one year before treatment, compared to 1251 infections over 17,831 person-years one year after treatment initiation (IRR = 1.11, 95% CI [1.03-1.19],
conclusionsWe found a modestly increased risk of SI in the year following therapy initiation, with the highest risk in the first three months. This risk was associated with certain baseline factors, highlighting the need for thorough risk assessment when starting treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.